Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803

Journal of Clinical Oncology

Volumn 27, Issue 31, 2009, Pages 5182-5188

  Arndt, Carola A S ^a   Stoner, Julie A ^a   Hawkins, Douglas S ^a   Rodeberg, David A ^a   Hayes Jordan, Andrea A ^a   Paidas, Charles N ^a   Parham, David M ^a   Teot, Lisa A ^a   Wharam, Moody D ^a   Breneman, John C ^a   Donaldson, Sarah S ^a   Anderson, James R ^a   Meyer, William H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION COMPLICATION; LEUKOPENIA; LIVER DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOSARCOMA; SARCOMA; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNDIFFERENTIATED CARCINOMA; CANCER STAGING; DISEASE FREE SURVIVAL; INFANT; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM STAGING; RHABDOMYOSARCOMA; TOPOTECAN; VINCRISTINE;

EID: 70449698239     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.3768     Document Type: Article

References (26)

1. Gurney JG, Young JL, Roffers SD, et al: Soft tissue sarcomas, in Ries LAG, Smith MA, Gurney JG, et al (eds): Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD, NIH publication 99-4649, 1999, pp 111-123
2. Raney RB, Anderson JR, Barr FG, et al: Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 23:215-220, 2001
3. Pappo AS, Shapiro DN, Crist WM, et al: Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 13:2123-2139, 1995
4. Maurer HM, Beltangady M, Gehan EA, et al: The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 61:209-220, 1988
5. Maurer HM, Gehan EA, Beltangady M, et al: The Intergroup Rhabdomyosarcoma Study-II. Cancer 71:1904-1922, 1993
6. Crist W, Gehan EA, Ragab AH, et al: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13:610-630, 1995
7. Crist WM, Anderson JR, Meza JL, et al: Intergroup Rhabdomyosarcoma Study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 19:3091-3102, 2001
8. Baker KS, Anderson JR, Link MP, et al: Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: Results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 18:2427-2434, 2000
9. Spunt SL, Smith LM, Ruymann FB, et al: Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Clin Cancer Res 10:6072-6079, 2004
10. Pappo AS, Lyden E, Breneman J, et al: Upfront window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An Intergroup Rhabdomyosarcoma Study. J Clin Oncol 19:213-219, 2001
11. Walterhouse DO, Lyden ER, Breitfeld PP, et al: Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: A Children's Oncology Group study. J Clin Oncol 22: 1398-1403, 2004
12. Saylors RL III, Stine KC, Sullivan J, et al: Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 19: 3463-3469, 2001
13. Nitschke R, Parkhurst J, Sullivan J, et al: Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 20:315-318, 1998
14. Anderson JR, Ruby E, Link M, et al: Identification of a favorable subset of patients (pts) with metastatic (MET) rhabdomyosarcoma (RMS): A report from the Intergroup Rhabdomyosarcoma Study Group (IRSG). Proc Am Soc Clin Oncol 16, 1997 (abstr 1836)
15. Arndt C, Hawkins D, Anderson JR, et al: Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol 22:1894-1901, 2004
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
18. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
19. Lan KKG, DeMets DL: Discrete sequential boundaries of clinical trials. Biometrika 70:659-663, 1983
20. Ortega JA, Donaldson SS, Ivy SP, et al: Venoocclusive disease of the liver after chemotherapy with vincristine, dactinomycin, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center. Cancer 79:2435-2439, 1997
21. Grier HE, Krailo MD, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694-701, 2003
22. Walterhouse DO, Meza JL, Raney RB, et al: Dactinomycin (A) and vincristine (V) with or without cyclophosphamide (C) and radiation therapy (RT) for newly diagnosed patients with low-risk embryonal/botryoid rhabdomyosarcoma (RMS). An IRS-V report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (STS COG). J Clin Oncol 24:502s, 2006 (suppl; abstr 9001)
23. Houghton PJ, Cheshire PJ, Hallman JC, et al: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)- carbonyloxycamptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 53:2823-2829, 1993
24. Houghton PJ, Cheshire PJ, Hallman JC II, et al: Efficacy of topoisomerase I inhibitors, topotecan, and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393-403, 1995
25. Furman WL, Stewart CF, Poquette CA, et al: Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815-1824, 1999
26. Pappo AS, Lyden E, Breitfeld P, et al: Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol 25:362-369, 2007